Advanced Catheter Cleared for Marketing
June 14 2004 - 11:49AM
PR Newswire (US)
Advanced Catheter Cleared for Marketing STEWARTVILLE, Minn., June
14 /PRNewswire-FirstCall/ -- Rochester Medical Corporation
(NASDAQ:ROCM) today announced FDA clearance for the advanced
Hydrophilic Antibacterial Intermittent Catheter. The Company also
announced its current intention to introduce the advanced catheter
to the market this fall under the Rochester Medical(R) brand, and
thereafter through private label arrangements. The new catheter
combines both of the Company's proprietary technologies into a
single device, providing both the advantages of the Company's
Infection Control Antibacterial Technology and the advantages of
its virtually friction free Hydrophilic Surface Technology. The
result is an easy to use, comfortable device, which gently
medicates the urethral tract during each catheterization, and is
designed to minimize the incidence of infection often associated
with use of intermittent catheters. The device is a single use,
disposable product for homecare use by people with urine retention
problems and for use by hospitals and clinics to maintain proper
bladder drainage, Anthony J. Conway, Chairman and Chief Executive
Officer of Rochester Medical Corporation, said, "I am very proud to
make this announcement. Rochester Medical Corporation can now offer
the most advanced and most comprehensive intermittent catheter
technology in the world today. Urinary tract infection is a
significant concern for a large patient population who must
catheterize themselves daily. We believe our new catheter can help
minimize the incidence of such infections. This new catheter is the
only intermittent catheter to offer the combined benefits of
antibacterial and hydrophilic coatings. It will be available in
several popular configurations at prices competitive with other
manufacturer's standard products." Commenting on the current
quarter, Conway went on to say that "based on performance to date
and our current expectations regarding the outlook for the
remainder of the quarter, I expect the Company will experience
record quarterly revenue and earnings." The immediately preceding
statement contains forward-looking statements that involve risks
and uncertainties, including the uncertainty of gaining acceptance
of the anti-infection catheters and hydrophilic catheters in the
marketplace, the uncertainty of new product introductions, the
uncertainty of gaining new strategic or private label
relationships, the risk that unforeseen developments could
materially affect the Company's quarterly financial performance,
the uncertainty of timing of private label sales revenues
(particularly international customers), FDA and other regulatory
review and response times, as well as other risk factors listed
from time to time in the Company's SEC reports and filings,
including, without limitation, the section entitled "Risk Factors"
in the Company's Annual report on Form 10-K (Part II, Item 6) for
the year ended September 30, 2003. Rochester Medical Corporation
develops, manufactures, and markets latex- free disposable medical
catheters and devices for urological and continence care
applications. The Company markets under its own Rochester Medical
brand and under private label arrangements. For further
information, please contact Anthony J. Conway, President and Chief
Executive Officer of Rochester Medical Corporation at (507)
533-9600. Rochester Medical is available on its website at
http://www.rocm.com/ . DATASOURCE: Rochester Medical Corporation
CONTACT: Anthony J. Conway, President and Chief Executive Officer
of Rochester Medical Corporation, +1-507-533-9600 Web site:
http://www.rocm.com/
Copyright
Rochester Medical Corp. (MM) (NASDAQ:ROCM)
Historical Stock Chart
From May 2024 to Jun 2024
Rochester Medical Corp. (MM) (NASDAQ:ROCM)
Historical Stock Chart
From Jun 2023 to Jun 2024